BrainStorm Cell Therapeutics Inc (BCLI)

[early_retirement2]

UPDATE

BrainStorm to Provide Corporate Update at the BIO International Convention



HACKENSACK, N.J. and PETACH TIKVAH, Israel, June 14, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company will present a corporate overview at the BIO International Convention, taking place June 19-22 at the San Diego Convention Center in San Diego, California.

Presentation Details

Date: Wednesday, June 21
Time: 2:00pm Pacific Time
Presenter: Chaim Lebovits, Chief Executive Officer, BrainStorm Cell Therapeutics
Location: San Diego Convention Center, Company Presentation Theater 3
Webcast: http://www.veracast.com/webcasts/bio/internationalconvention2017/96236165162.cfm

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult mesenchymal stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTS

Media:
Uri Yablonka
Brainstorm Cell Therapeutics Inc.
Phone: [phone]
[e-mail]

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: [phone]
[e-mail]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-to-provide-corporate-update-at-the-bio-international-convention-300473770.html

SOURCE BrainStorm Cell Therapeutics Inc.